Products Categories
| CAS No.: | 231277-92-2 |
|---|---|
| Name: | Lapatinib |
| Molecular Structure: | |
|
|
|
| Formula: | C29H26ClFN4O4S |
| Molecular Weight: | 581.067 |
| Synonyms: | GW572016;N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;Lapatinib base;Lapatinib & its intermediates;Lapatinib(TINIBS);GW 572016;GSK 572016;Lapatinib [INN]; |
| EINECS: | 1806241-263-5 |
| Density: | 1.381 g/cm3 |
| Boiling Point: | 750.7 °C at 760 mmHg |
| Flash Point: | 407.8 °C |
| Appearance: | Powder |
| Hazard Symbols: |
 T, F
|
| Risk Codes: | R10; R23/24/25; R34; R36/37/38 |
| PSA: | 114.73000 |
| LogP: | 7.68380 |
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 240444-70-62,3,5,6-Tetrafluor-4-(methoxymethyl)benzyl-2,2-dimethyl-3-(prop-1-en-1-yl)cyclopropancarboxylat
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 104458-24-4
2-(methylsulfonyl)ethylamine hydrochloride
- 231278-84-5
5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| Stage #1: 2-(methylsulfonyl)ethylamine hydrochloride With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 0.333333h; Stage #2: 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde With acetic acid In tetrahydrofuran at 40℃; for 2h; Stage #3: With sodium tris(acetoxy)borohydride In tetrahydrofuran at 25 - 40℃; for 3h; Concentration; | 100% |
| Stage #1: 2-(methylsulfonyl)ethylamine hydrochloride; 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde With N-ethyl-N,N-diisopropylamine In isopropyl alcohol at 50 - 60℃; for 4h; Stage #2: With sodium cyanoborohydride In isopropyl alcohol at 20℃; for 2h; | 92.6% |
| Stage #1: 2-(methylsulfonyl)ethylamine hydrochloride With sodium sulfate; triethylamine In methanol at 0℃; for 0.333333h; Stage #2: 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde With formic acid; sodium cyanoborohydride In tetrahydrofuran; methanol; N,N-dimethyl-formamide for 2h; pH=5 - 6; | 82% |
| Conditions | Yield |
|---|---|
| With triethylamine In dichloromethane at 25 - 30℃; Inert atmosphere; | 97% |
- 388082-78-8
lapatinib ditosylate
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| Stage #1: lapatinib ditosylate In ethyl acetate at 20℃; for 1h; Stage #2: With sodium carbonate In water; ethyl acetate for 1h; | 96.2% |
| With sodium carbonate In water; acetonitrile at 5 - 40℃; for 3.58333h; | 91% |
| With sodium carbonate In water; ethyl acetate at 22 - 70℃; for 3.25h; | 56% |
| Conditions | Yield |
|---|---|
| In tetrahydrofuran at 35 - 40℃; for 4h; | 90.3% |
- 231278-20-9
N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium dihydrogenphosphate In N,N-dimethyl-formamide at 80℃; for 5h; Temperature; Solvent; Reagent/catalyst; Inert atmosphere; | 89.8% |
- 49773-20-8
2-Methanesulfonyl-ethylamine
- 231278-84-5
5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| Stage #1: 2-Methanesulfonyl-ethylamine; 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde In methanol; dichloromethane at 20℃; Stage #2: With hydrogen In methanol; dichloromethane Inert atmosphere; | 85% |
| Stage #1: 2-Methanesulfonyl-ethylamine; 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde With sodium tris(acetoxy)borohydride; N-ethyl-N,N-diisopropylamine Stage #2: With toluene-4-sulfonic acid | 80% |
| Stage #1: 2-Methanesulfonyl-ethylamine; 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde With triethylamine In tetrahydrofuran; methanol for 3h; Stage #2: With methanol; sodium tetrahydroborate In tetrahydrofuran at 20℃; Cooling with ice; | 70% |
| Conditions | Yield |
|---|---|
| With acetic acid for 1h; Reflux; Industrial scale; | 84.2% |
- 1227853-05-5
N(1)-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-N,N-dimethylformamidine
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| With acetic acid for 1h; Reflux; Industrial scale; | 82.4% |
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| With 20% palladium hydroxide-activated charcoal; hydrogen In methanol at 20℃; under 2585.81 - 2844.39 Torr; | 81.67% |
- 845658-68-6
N-((5-bromofuran-2-yl)methyl)-2-(methylsulfonyl)ethanamine
- 944549-41-1
N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-bromo-quinazolin-4-amine
- 73183-34-3
bis(pinacol)diborane
- 231277-92-2
lapatanib
| Conditions | Yield |
|---|---|
| Stage #1: N-((5-bromofuran-2-yl)methyl)-2-(methylsulfonyl)ethanamine; bis(pinacol)diborane With bis-triphenylphosphine-palladium(II) chloride; potassium acetate In dimethyl sulfoxide at 75℃; for 5h; Inert atmosphere; Stage #2: N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-bromo-quinazolin-4-amine In dimethyl sulfoxide at 75℃; for 16h; Catalytic behavior; Temperature; Solvent; Reagent/catalyst; | 47% |
- 75330-75-5Butanoic acid, 2-methyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, (2S)-
- 71-00-1L-Histidine
- 169590-42-5Celecoxib
- 87333-19-5Ramipril
- 23593-75-1Clotrimazole
- 271-63-67-Azaindole
- 2152-44-5Betamethasone 17-valerate
- 7775-27-1Sodium persulfate
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
1. Introduction of Lapatinib
Lapatinib is one kind of off-white crystaline powder. The IUPAC Name of this chemical is N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine. Lapatinib belongs to Molecular Targeted Antineoplastic;anti-neoplastic;Pharmaceutical intermediate. Besides, the Classification Code of it is Antineoplastic; Antineoplastic Agents; Dual EGFR/erbB2 Inhibitors; Enzyme Inhibitors; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors. In addition, its solubility in water is 0.007 mg/mL and in 0.1N HCl is 0.001 mg/mL at 25°C.
2. Properties of Lapatinib
Physical properties about Lapatinib are:
(1)H bond acceptors: 8; (2)H bond donors: 2; (3)Freely Rotating Bonds: 10; (4)Polar Surface Area: 97.15 Å2; (5)Index of Refraction: 1.644; (6)Molar Refractivity: 152.46 cm3; (7)Molar Volume: 420.6 cm3; (8)Surface Tension: 57.6 dyne/cm; (9)Density: 1.381 g/cm3; (10)Flash Point: 407.8 °C; (11)Enthalpy of Vaporization: 109.42 kJ/mol; (12)Boiling Point: 750.7 °C at 760 mmHg; (13)Vapour Pressure: 2.03E-22 mmHg at 25°C; (14)Protein binding: >99%; (15)Bioavailability: Variable, increased with food; (16)Half life: 24 hours; (17)Excretion: Mostly fecal; (18)Metabolism of Lapatinib: Hepatic, mostly CYP3A-mediated.
3. Structure Descriptors of Lapatinib
(1)InChI: InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
(2)InChIKey: InChIKey=BCFGMOOMADDAQU-UHFFFAOYSA-N
(3)Smiles: c1cc2ncnc(Nc3ccc(c(c3)Cl)OCc3cccc(c3)F)c2cc1c1oc(cc1)CNCCS(=O)(=O)C
4. Toxicity of Lapatinib
Routes: Oral
5. Uses of Lapatinib
Lapatinib (CAS NO.231277-92-2) is used as a treatment for women's breast cancer in patients. These patients have HER2-positive advanced breast cancer, which has progressed after previous treatment with other chemotherapeutic agents, such as taxane-derived drugs, anthracycline, or trastuzumab. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2). However, the most common side effects are diarrhea, fatigue, nausea and rashes. Lapatinib is regarded as well tolerated, Like many small molecule tyrosine kinase inhibitors.